Validation of Lysyl Oxidase-Like 2 (LOXL2) as Prognostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NET) Using an Independent Cohort.

#1316

Introduction: LOXL2 is a key protein to epithelial to mesenchymal transition. We showed LOXL2 has a role as a prognostic marker in 115 GEP-NET cases (training cohort (TC)).

Aim(s): Validation of LOXL2 expression by immunohistochemistry (IHC) in an independent cohort.

Materials and methods: Formalin-fixed paraffin-embedded samples (FFPE) of consecutive GEP-NET patients from 1999 to 2010 who underwent surgery in a different Spanish institution constituted the validation cohort (VC). Tissue microarrays were constructed from 2 non-necrotic areas of tumour foci. LOXL2 expression was studied by IHC and classified as presence (P) vs absence (A). Log rank test and Cox regression were used to study Disease Free Survival (DFS) and Overall Survival (OS). Univariate and multivariable analysis (MVA) were performed.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Barriuso J, Benavent M, Lamarca A, Bernal E, Guerra-Pastrian L,

Keywords: LOXL2,